140 results about "PC12 cell line" patented technology

Disclosed is a bio-electrospinning technique for preparing a cell-containing, oriented, continuous tubular scaffold, made of biodegradable polymer, designed for use as a nerve guide conduit (NGC) in nerve regeneration. With a coaxial spinneret, the PC-12 cell medium solution was co-electrospun into a core of tubular fibers, with PLA on the outer shell. The resulted fibers' morphology was characterized via SEM and optical microscopy, and following structural characteristics were found: 1. the larger, hollow fibers had diameters in tenth of microns and wall thicknesses around few microns, 2. an orientation in a preferred direction with the aid of a high-rotating collection device. The fluorescent PC12 cells embedded within the scaffold were cultured and nerve growth factor was added. We observed cells could not only survive the process, but also sustain their viability by undergoing differentiation process, extending neurite along the micro tubular scaffold in the desired direction. All these results demonstrate its potential application for advanced NGC.

The invention relates to a 7 and 20 dehydro-silybin dialky ether and preparation method and medicine use thereof. The compounds are capable of obviously preventing the lipid superoxide induced by the free radical from being generated; effectively protecting the injury rat adrenal pheochromocytoma cells PC12 due to hydrogen dioxide, namely with oxidation resistance injury protection function on thePC12 cells which simulate the cranial nerves; preventing the brain cells and the cranial nerves from being oxidized and controlling the neurodegenerative diseases such as senile dementia. In addition, the compounds have strong chelation on the ferrous ion. The pharmacodynamics result shows that: the compounds are anticipated to prepare the medicine for controlling the neurodegenerative diseases.

The invention relates to Isopentenyl-oxyl substituted dehydrogenized silybin ether and the preparation method and the application thereof. The compound has the activity of eliminating extracorporeal extracorporeal 1-diphenyl-2-picrylhydrazyl radical, the activity of obviously inhibiting the generation of lipid peroxide induced by radical and the function of powerfully preventing the damage of therat adrenal pheochromocytoma PC12 cells due to the hydrogen peroxide, i.e. the function of preventing the oxidative damage of the PC12 cells simulating the brain nerve cells, thereby playing a positive role in preventing the brain cell tissue oxidation and brain never oxidation and preventing and treating the senile dementia and other neurodegenerative diseases. The pharmacodynamic result shows that 7-site substituted dehydrogenized silybin ether can be expectantly used for preparing the medicament for preventing and treating the neurodegenerative diseases.

The invention relates to a novel scutellarin aglycon 4 (1)-position carbamate derivant (1), a preparation method and the application thereof. A pharmacological experiment proves that the compounds have obvious inhibitory activity of acetylcholinesterase and have protective effect with different degrees on PC12 cell trauma induced by H2O2, so the compounds can be used for preparing the drugs for treating neurodegenerative diseases such as vascular dementia, AD (presenile dementia), etc.

A novel electrically conductive polymer composite composed of polycaprolactone fumarate-polypyrrole (PCLF-PPy) for applications in nerve regeneration is disclosed. The synthesis and characterization of PCLF-PPy and in vitro studies showing PCLF-PPy supports both PC12 cell and Dorsal Root Ganglia neurite extension. PCLF-PPy composite materials were synthesized by polymerizing pyrrole in pre-formed scaffolds of PCLF resulting in an interpenetrating network of PCLF-PPy. PCLF-PPy composite materials possess electrical conductivity up to 6 mS cm⁻¹ with compositions ranging from 5-13.5 percent polypyrrole of the bulk material. Surface topographies of PCLF-PPy materials show microstructures with a RMS roughness of 1195 nm and nanostructures with RMS roughness of 8 nm. PCLF-PPy derivatives were synthesized with anionic dopants to determine effects on electrical conductivity and to optimize the chemical composition for biocompatibility. In vitro studies using PC12 show PCLF-PPy composite materials induce a higher cellular viability and increased neurite extension compared to PCLF. PCLF-PPy composites doped with either naphthalene sulfonic acid or dodecyl benzene sulfonic acid are determined to be the optimal materials for electrical stimulation. In vitro studies showed significant increases in percentage of neurite bearing cells, number of neurites per cell and neurite length in the presence of ES compared to no ES. Additionally, extending neurites were observed to align in the direction of the applied current. Electrically conductive PCLF-PPy scaffolds possess material properties necessary for application as nerve conduits. Additionally, the capability to significantly enhance and direct neurite extension by passing electrical current through PCLF-PPy scaffolds renders them even more promising as future therapeutic treatments for severe nerve injuries.

The invention relates to a silibinin flavonolignan and its medicine salt or solvates. The invention also relates to the method preparing its important mediate and its drug combination and medical application. The compound can protect primary hepatocyte from oxidative damage for SD newly born rat hepatitis virus, so it is expected to be used as drug preventing liver damage. The compound can remove superoxide anion free radical and diphenyl picryl phenylhydrazine free radical, inhibit free radical from inducing generation of fat oxidatant, protect PC 12 cell from being damaged by free radical, so it is expected to be used as drug treating diseases caused by free radical.

The invention relates to an aminosalicylic acid derivative. The structure of the aminosalicylic acid derivative accords with the following general formula (I). At least one of R1, R2, R3 and R5 is -OH; when R1, R2, R3 and R5 are not -OH, R1, R2, R3 and R5 are -H, -OCH3, -F, -Cl, -Br, -CF3 or -NO3; R4 is -OCH3, -F, -Cl, -Br, -CF3 or -NO3; R6 and R7 are -COOH or -OH. When R6 is -COOH, R7 is -OH; when R6 is -OH, R7 is -COOH. In the invention, target compounds have strong protection function on PC12 cell injuries caused by glutamate. And the target compounds block the coupling between PSD-95 and nNOS by specificity to develop the pharmacological action.

The invention discloses application of bioflavonoids or polyphenol compounds to preventing and treating Parkinson diseases. The bioflavonoids or polyphenol compounds can be selected from kaempferol-3-O-rutinoside, dehydrated carthamin yellow B, 6-hydroxyl kaempferol-3, 6-dioxygen glucoside, (2S)-4', 5-dihydroxyl-6, 7-dioxygen flavonone glucoside, rutin, quercetin, vanillina or isovanillin. Through large amount of experiments, the bioflavonoids or polyphenol compounds have activity of interacting with protein DJ-1 related to the Parkinson diseases. Through further experiments, the bioflavonoids or polyphenol compounds have pharmaceutical activities for resisting oxidative stress, preventing apoptosis of PC12 cells or primary nerve cells induced by the oxidative stress, inhibiting active oxygen generation in cells, improving activity of tyrosine hydroxylase, and the like, and can be used for preventing or treating the Parkinson diseases.

The present invention relates to an anti-free radical oxidation, liver-protective, senile dementia preventing and anti-aging active dehydrogenation silybin double-ester derivative and the related medicinal salt or solvent compound. The invention also relates to the preparation method for the compound on the formula 1, as well as the related medication compounds and the curatorial uses. The compound of the invention can protect the liver cells of a rat liver cell injury in vitro model, which can be expected to prevent liver damage in drug use; the compound of the invention is provided with the biological activities of in vitro removing superoxide anion free radicals and diphenyl-benzyl-hydrazine free radicals, and restraining generation of grease peroxide induced by free radicals. The compound can strongly confront the PC12 cells damage caused by free radicals, which can be expected to prevent various diseases caused by free radicals in drug use.

The intervention relates to a CHO (Chinese Hamster Ovary) cell strain of an efficiently-expressed recombinant human nerve growth factor and a construction method thereof and belongs to the field of biotechnology. The preservation number of the cell strain is CGMCC No. 4541, and the recombinant human nerve growth factor (rhNGF) with biological activity can be stably expressed. The invention also discloses a method for constructing the CHO cell strain; and through cell transfection, gene amplification and subcloning screening carried out on an amplified cell line, an efficiently-expressed monoclonal cell strain suitable for serum-free suspension culture is obtained. The invention simultaneously discloses a recombinant human nerve growth factor sequence secretly expressed by the CHO cell strain; and the secrete recombinant human nerve growth factor has good biological activity, so that PC12 multiplication can be kept outside a human body, PC12 cell differentiation is induced, and the chick embryo dorsal root ganglion nerve fiber growth is stimulated to lay a good foundation for the large-scale industrialization preparation of the recombinant human nerve growth factor.

The invention relates to an isaria cosmopaltriae yasuda polysaccharide and applications thereof in preparing a nerve-protective and anti-aging drug. The isaria cosmopaltriae Yasuda polysaccharide is obtained by adopting the following method: drying isaria cosmopaltriae yasuda materials, grinding and sieving with a pharmacopoeia sieve NO.2, and refluxing and extracting powder twice with water at 90 DEG C, wherein each time lasts for two hours; performing decompression concentration to an extracting liquid, then adding anhydrous ethanol, and settling overnight at 4DEG C-25DEG C; centrifuging for 10-30min at 3000r/min; and drying the settling part to obtain isaria cosmopaltriae yasuda polysaccharide (JCHCPS). The isaria cosmopaltriae yasuda polysaccharide can obviously inhibit aging injury of glutamic acid-induced PC12 cells, stop the release of cells LDH, improve the survival rate of the cells, reduce the level of oxygen radicals in the cells, and improve the activity of glutathione reductase (GSH-Px) and superoxide dismutase (SOD), and shows better antioxidant activity in experiments of clearing DPPH.superoxide anion (O2.-).

The invention provides a cycloastragenol extract. A preparation method of the cycloastragenol extract comprises the steps that coarse astragalus membranaceus powder is extracted by using an alkaline alcohol water solution with a pH value of 11-13 to obtain a coarse astragaloside extract; the obtained coarse astragaloside extract is enriched and purified through macroporous resin to obtain an astragaloside extract; the obtained astragaloside extract is subjected to Smith degradation to obtain the cycloastragenol extract. For cycloastragenol extract preparation, an optimum extraction method is obtained through multiple times of tests conducted on the pH value, sodium periodate dosage and methanol concentration in the extraction conditions. The method is good in reproducibility, simple and easy to operate. The prepared cycloastragenol extract can obviously retard senility hurt of H2O2 to PC12 cells, and improve cell vitality, and the cycloastragenol extract obtained by adopting the preparation method has certain anti-aging activity and can be applied to preparation of anti-aging medicines and health-care products.

The invention discloses a device for evaluating the neuron-like differentiation degree of a PC12 cell. The device consists of a hopping probe ion conductance microscope (HPICM) and a patch clamp system. An evaluating method comprises the following steps of: obtaining a glass microprobe for observing the micro-topography of the PC12 cell with an HPLCM technology; scanning and imaging the surface topographies of living neuron-like PC12 cell at different NGF (Nerve Growth Factor) induced differentiation time points with the HPLCM technology; analyzing the scanning and imaging with image processing software installed in an HPLCM system; obtaining the glass microprobe which is suitable for performing whole cell recording by adopting a patch clamp technology; recording the ion channel current of the living neuron-like PC12 cell under physiological conditions by adopting the patch clamp technology; and computing corresponding inward current and current density by using the ion channel current of the PC12 cell. The invention has the advantages: high operability is achieved by combining the HPLCM technology with the patch clamp technology, and the neuron-like differentiation degree of the PC12 cell can be qualitatively, quantitatively and comprehensively analyzed and evaluated more accurately on the aspects of structures and functions.

Neurotrophin binding to its specific receptors Trk A and p75 leads to the activation of multiple signalling cascades, culminating in neuroprotective and regenerative effects, including neuronal survival and neurite outgrowth. Neurotrophic factors have been used for the treatment of several neurodegenerative diseases. However, their use is limited by their inability to cross the blood-brain barrier, their short half life and their side effects. Small molecule neurotrophin mimetics may be beneficial in treating a number of neurodegenerative disorders. The present invention shows the capacity of nerve growth factor agonist molecules of Formulae I-IV, as defined in the specification, to induce differentiation in PC 12 cells, promote survival in RN22 cells and activate Trk A, IkBa and SAPK/JNK phosphorylation to various extents in both cell lines. In addition these molecules were able to ameliorate acute experimental autoimmune encephalomyelitis (EAE), a multiple sclerosis (MS) animal model, inhibiting brain inflammation and reducing brain damage. We also observed suppression in the production of pro-inflammatory genes like the inducible nitric oxide synthase. These small molecules with NGF agonist activity may be beneficial for MS and other neurodegenerative diseases due to its neuroprotective and immunomodulatory properties.

The invention discloses an application of ginsenoside-Re in protecting nerve cells, and belongs to the technology field of medicines. According to the invention, the ginsenoside-Re has the effect of protecting cerebral ischemia, cerebral ischemia reperfusion injury, Parkinson disease, Alzheimer disease and PC12 cells; and can be used for preparing new drugs for preventing and treating neurological diseases such as Parkinson disease, Alzheimer disease, cerebral apoplexy and cerebral ischemia. For a mouse model, the dose of ginsenoside-Re is 8-26mg/kg; for a rat model, the dose of ginsenoside-Re is 5-26mg/kg, and for cell experiments, the dose is 10<-5>-10<-8>mol/L.

The invention provides a preparation method of a ginseng extract containing endogenous polypeptides, the ginseng extract, a determination method of the polypeptides in the ginseng extract, a medicine or medicine composition containing the ginseng extract and an application of the medicine or medicine composition. The preparation method comprises the steps of grinding a ginseng medicinal material into powder, extracting by an organic solvent or formic acid, separating the extract liquid by a column, concentrating the eluent, and thus obtaining the ginseng extract with the endogenous ginseng polypeptides as a main component. The determination method of the ginseng extract comprises the steps that a Nano LC-LTQ-Orbitrap technology is used for analysis, a Swiss-Prot database is searched by PEAKS, 308 endogenous polypeptides are identified from the ginseng extract totally, amino acid sequences of the polypeptides are SEQ ID No.1-125 and SEQ ID NoS.1-183, and the molecular weight is ranged from 300 to 7000 Da. Through UHPLC-Q-TOF detection, the content of the ginseng polypeptides of the extract is more than 30% by ProgenesisQI software analysis. The ginseng extract is also subjected to cell experiments, and experimental results indicate that the extract has a function of promoting the proliferation of PC 12 cells.

The invention discloses an electrochemical biosensor for detecting intracellular hydrogen peroxide on line based on a paper chip in combination with a screen printing electrode. The prepared nano-platinum/multi-walled carbon nanotube material is modified on the surface of the screen printing electrode and organically combined with a self-made integrated cell culture platform-paper-based chip to manufacture a biosensor for monitoring PC12 cells (adrenal pheochromocytoma cells) that releases hydrogen peroxide on line. The biosensor is connected with an electrochemical workstation to monitor theactivities of PC12 cells and Alzheimer's disease (AD) model cells, has good specificity and high sensitivity, and provides a novel method for research on cell activity monitoring and other related fields.

The present invention provides a compound as represented by formula I, which has a structure as follows: R1 and R2 are glycosyl, R3 is H, hydroxyl or methoxyl; R4 is hydroxyl or methoxyl; and R5 is H, hydroxyl or methoxyl. The present invention further provides a preparation method and purpose of the compound. In the present invention, 8,4'-oxyl neolignan glycoside compound is obtained from dendrobium nobile, inhibits PC12 cell neurotoxicity caused by glutamic acid, protects nerve cells in certain degree, and can be used for treatment of neurodegenerative disorder.

The invention discloses a thuja extract and application thereof in preparation of medicaments for preventing and treating neurodegenerative diseases. The thuja extract is prepared by the following steps of: taking thuja wood and processing the wood into pieces or wood shavings, adding a solvent for extraction, wherein the extraction solvent is water or ethanol or mixture of the water and the ethanol, and the solvent is 5 to 20 times weight of the thuja wood, performing leaching or heating reflux extraction, and recovering the solvent from the extract so as to obtain extractum; adding water accounting for 5 to 20 times weight of the extractum, heating to fully dissolve, filtering while hot, concentrating the filter liquor to the relative density of more than 1.05, and obtaining degreased extractum; and adding the ethanol into the degreased extractum so as to obtain the 50 to 80 percent alcohol, standing for 1 to 72 hours, filtering, and recovering the solvent from the filter liquor so as to obtain the thuja extract. The thuja extract is subjected to PC12 cell tests and anti-aging dementia nematode model tests, and the results prove that the thuja extract can obviously suppress apoptosis of the MPP+ mediated PC12 cells and prolong the nematode controlling time, has prevention and treatment effect on the Parkinson's disease and senile dementia, and can be used for preparing medicaments for preventing and treating the Parkinson's disease and senile dementia.

The invention relates to a dehydrogenated silibinin substituted by meta-chlorobenzene formoxyl, a preparation method and pharmaceutical applications thereof, in particular to a preparation method and applications of 2,3-dehydrogenated silibinin substituted by 23-site meta-chlorobenzene formoxyl. The compound has applications of inhibiting activity of production of lipid superoxide induced by free radical and can be expectedly used for preparing medicine for prevention and treatment of acute and chronic liver damage, hepatitis and cerebral atherosclerosis which are caused by the lipid superoxide. The compound further shows very strong resistance for PC12 cell damage caused by free radical and can be expectedly developed into medicine for protecting cranial nerve from oxidation and preventing and treating senile dementia. Besides, the compound has strong xanthine oxidase activity inhibition and can be expectedly developed into medicine for preventing and treating diseases caused by xanthine oxidase.

The invention discloses a novel iridoids compound with a structure shown in formula I and a neuroprotective effect thereof, a preparation method of the compound I and an application of a pharmaceutically acceptable salt of the compound in the preparing of medicines for treating and preventing central nervous system diseases, and an application of the compound or the pharmaceutically acceptable salt thereof in the preparing of medicines with nerve cell protection effects. The cell survival rate of a 18mg/L group of the compound with the structure shown in formula I is obviously higher than a glutamic acid group (P(0.01)), so that the compound with the structure shown in formula I has an obvious protection effect on PC12 (pheochromocytoma-12) cells damaged by glutamic acid and can be used for preventing and treating central nervous system diseases such as cerebral infarction, Alzheimer disease, Parkinson disease, anxiety disorder and the like.

The invention provides a cucurbitane type triterpene compound and an extraction method. The extraction method comprises the following steps: grinding bitter gourd fruit into powder; performing digestion in methanol; extracting with ethyl acetate and water to obtain crude extracts of water layer and ester layer; separating and purifying the crude extracts respectively to obtain the target compound.The cucurbitane type triterpene compound provided by the invention is a novel compound, the extraction method is simple and easy, and the yield is high. The cucurbitane type triterpene compound provided by the invention remarkably increases the neurite differentiation rate of PC12 cells in an in-vitro screening model resisting Alzheimer's disease, and can be used for preparing medicines and healthcare products resisting Alzheimer's disease. The invention provides a basis for new drug research and development as well as basic research against Alzheimer's disease, and has important practical significance. The structural formula of the cucurbitane type triterpene compound is shown in the specification.

The invention discloses salidroside analogues as well as a preparation method and application thereof. The preparation method comprises the steps such as preparing an intermediate, namely acetyl glucoside, preparing the salidroside analogues and other steps. The obtained products can be used for low-sugar low-serum damage protection of PC12 cells, and the treatment of central nervous and peripheral nervous injury and wasting diseases. In the preparation method, when an aromatic ring contains a hydroxyl group, an acetyl group is used for protecting the hydroxyl group, so that the acetyl group is conveniently removed at the same time of the removal of the acetyl group on a sugar ring, thus avoiding the use of allyl and benzyl protection, shortening the reaction process and lowering the cost; the used solvent is a low-residue aprotic mixed solvent of dichloromethane and diethyl ether, and the glucoside is formed after reacting is performed at room temperature for 10 hours, thus avoiding the use of other more toxic solvents; by using a common inorganic reagent, namely potassium carbonate, the acetyl group is removed, and during column chromatography, dichloromethane is used for substituting for chloroform, thus contributing to the health of operators; and trace iodine is used as a catalyst, anhydrous calcium sulfate is used as a dewatering agent and a powdery 4-angstrom molecular sieve is added.

The invention discloses novel medicinal use of a genipin derivative and in particular to an application thereof in preparing a drug for preventing and treating neurodegenerative disease. The genipin derivative is as shown in a structural formula (I). Verified by an H2O2 induced PC12 cell oxidative damage model and a PD animal model test, the genipin derivative has an obvious neuroprotective effect and has an important application prospect in preparing the drug related to prevention and treatment of neurodegenerative disease.

The invention discloses a centella extract. The preparation method comprises the following steps: with an ethanol solution as a solvent, carrying out crude extraction on centella by using an ultrasonic extraction method; and with an AB-8 resin separation column and the ethanol solution as eluents, separating out effective components, wherein the target components eluted by 30%-50% of ethanol and 51%-75% of ethanol solution are the centella extracts. The centella extract disclosed by the invention is capable of promoting cell proliferation and differentiation of a neuron model PC12 without NFG induction, and can be applied to treatment of depressive disorder, and related diseases of various nerve injuries and neuronal apoptosis. The extraction method provided by the invention is simple in process, low in cost and high in efficiency.

The invention belongs to the technical field of medicinal chemistry and discloses a N-(1,2,3,4-tetrahydroisoquinolinyl)-feruloylagmatine-O-alkylamine compound (I) and pharmaceutically acceptable salt, and a preparation method and application thereof. The structure is as shown in a formula I. The compound (I) provided by the invention has high butyrylcholine esterase inhibiting activity, anti-oxidation activity and Abeta1-42 aggregation inhibiting activity, and has remarkable neuroprotective function on PC12 cell injury induced by hydrogen peroxide, which indicates that the compound is a multi-target-point inhibitor. The compound further shows a good effect of treating alzheimer disease in in-vivo experiments, and has low toxicity and a good clinical application prospect.

The invention discloses a use of osteocalcin for preparing medicine for treating Parkinson's diseases. The effects that exogenous application of the osteocalcin can relieve the dyskinesia of a rat model with the Parkinson's diseases and can reduce the substantia nigra dopaminergic neuron loss, and the PC12 cell apoptosis caused by 6-OHDA can be reduced through AKT/GSK path in vitro. Therefore theosteocalcin as a small molecule polypeptide hormone capable of passing through blood brain barrier can become fire-new medicine for preventing and treating the occurrence and the development of the Parkinson's diseases.

The invention relates to scutellaprostin compounds, methods for preparing the same and pharmaceutical uses of the same. Particularly, the invention relates to preparation methods and pharmaceutical uses of A cyclo-dioxane scutellaprostin compounds capable of inhibiting the activities of xanthine oxidase, protecting brain nerve cells from oxidative damages and preventing and treating senile dementia. The compounds have strong inhibition effect on the activities of the xanthine oxidase and are expected to be used to prepare drugs or pharmaceutical compositions for preventing and treating diseases such as gout caused by the xanthine oxidase. The compounds have strong anti-oxidative damage and protective effects on PC12 cells simulating brain nerve cells and are expected to be used to prepare drugs or pharmaceutical compositions for protecting brain nerves, preventing aging and preventing and treating senile dementia.